Relationships of CYP3A4 gene 18B polymorphisms with efficacy and adverse reactions in advanced NSCLC patients with EGFR gene mutation
CHENG Yanfang
FEI Jing
WANG Yanna
WANG Hui
MENG Lingli
GONG Ping
Abstract：Objective To explore the relationships of cytochrome 3A4 (CYP3A4) gene 18B polymorphisms (CYP3A4 * 18B) on the efficacy and adverse reactions in advanced non-small-cell lung cancer (NSCLC) patients with EGFR gene mutation.Methods Forty-four patients with newly diagnosed advanced NSCLC were chosen and treated with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) gefitinib 250 mg,once a day,or erlotinib 150 mg,once a day;when the patients could not tolerate the adverse reactions,we stop the medication.PCR and the direct sequencing were carried out to determine the mutations of CYP3A4 * 18B before treatmeut,and then we compared the efficacy (objective response rate,disease control rate) and adverse reactions between mutant type and wild type patients.Results The mutation frequency of CYP3A4 * 18B gene was 36.4％ (16/44),among which wild type homozygote accounted for 63.6％ (28/44),mutant heterozygote accounted for 34.1％ (15/44),and mutant homozygote accounted for 2.3％ (1/44).There was no significant difference in efficacy of EGFR-TKI between wild type and mutant type patients (all P ＞0.05).Patients with CYP3A4 * 18B gene wild type had a higher incidence of rash than that of the mutant type (P ＜0.05).Conclusion The polymorphism of CYP3A4 gene 18B is not related to the efficacy of EGFR-TKI for advanced NSCLC patients with EGFR gene mutation,but is related to the adverse reactions of drugs.
Keywords：non-small-cell lung cancercytochrome 3A4epidermal growth factorgene polymorphismtyrosine kinase inhibitortherapeutic outcomeadverse reactions
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 1-4 )